Retatrutide — nicknamed the "triple G" or "triple agonist" — is the most-talked-about weight loss medication of 2026. In May 2026, Eli Lilly reported Phase 3 results showing average weight loss of about 28% at the highest dose, more than any GLP-1 medication currently on the market. But retatrutide is not FDA approved, and it isn't legally available by prescription yet. Here's what retatrutide is, what the research shows, when it might be available, why "research peptide" versions are risky, and what you can do right now at Alpine Health & Wellness in Kalispell, MT.
Retatrutide is an investigational once-weekly injection that activates three hormone receptors at once:
Semaglutide (Wegovy, Ozempic) targets one of these receptors. Tirzepatide (Zepbound, Mounjaro) targets two. Retatrutide targets all three, which researchers believe explains its larger effect.
In the Phase 3 TRIUMPH-1 trial, reported May 21, 2026, participants on the highest dose (12 mg weekly) lost an average of 28.3% of their body weight — roughly 70 pounds — over 80 weeks. An earlier Phase 2 trial published in the New England Journal of Medicine in 2023 showed about 24% average weight loss at 48 weeks.
For comparison, average weight loss in the major trials of currently available medications was about 15% for semaglutide and up to about 21% for tirzepatide.
Retatrutide's side effects look similar to other GLP-1 medications, and they're dose-related. In TRIUMPH-1:
Researchers are also watching heart rate, which rose modestly in earlier trials, and long-term safety data is still being collected — including a large cardiovascular and kidney outcomes trial (TRIUMPH-Outcomes).
As of September 2026, retatrutide remains investigational. Lilly is expected to file for FDA approval after its remaining Phase 3 trials report, and industry analysts generally don't expect an approval decision before 2027. Even after approval, it typically takes additional time for supply, insurance coverage, and pricing to settle.
No — and this is the most important part of this article. Because demand is so high, retatrutide is being sold online as a "research peptide" labeled "not for human use." Those products:
The FDA has been actively scrutinizing the peptide market this year — read What the FDA's July 2026 Peptide Review Means for You for more. At Alpine Health & Wellness, we only use medications from legitimate, regulated sources under medical supervision.
If retatrutide is on your radar, you don't need to wait on the sidelines. Currently available options are highly effective for most people:
Starting now also means that if retatrutide is approved and becomes a good fit for you later, your provider will already know your history, labs, and how you tolerate incretin medications — which makes any future switch smoother and safer.
In trials, retatrutide has produced more average weight loss than tirzepatide. But it isn't approved, long-term safety data is still being gathered, and "most weight loss" isn't the right goal for everyone. For many people, tirzepatide or semaglutide already achieves their goals with a well-established safety record.
Not legally by prescription. Retatrutide is only available through clinical trials until the FDA approves it. Products sold online as "research peptides" are not approved for human use.
Ozempic (semaglutide) activates one receptor — GLP-1. Retatrutide activates three — GLP-1, GIP, and glucagon. The glucagon component may increase calorie burning and liver fat reduction, which may help explain its larger weight loss.
Any large, rapid weight loss can include muscle loss. Protecting muscle with protein and resistance training is important with every medication in this class. Learn more in Prevent Loss of Muscle Mass with Aging.
Most people are better served starting a proven, available treatment now. Excess weight carries ongoing health risks, and waiting a year or more for a new drug means delaying benefits you could have today. We're happy to talk through the trade-offs with you.
At Alpine Health & Wellness, Elizabeth, our Nurse Practitioner, builds personalized medical weight loss plans using safe, legitimate medications, comprehensive labs, and real follow-up support. We keep up with the research — including retatrutide — so you don't have to sort through the hype alone.
Call Alpine Health & Wellness in Kalispell, MT at 406-361-7421 or book an appointment online.
This article is for educational purposes only and is not medical advice. Retatrutide is an investigational medication that is not approved by the FDA. Information reflects publicly available research as of September 2026. Talk with a qualified healthcare provider before starting any weight loss medication.
